Logo

BMGL

Basel Medical Group Ltd Ordinary Shares

BMGL

Basel Medical Group Ltd Ordinary Shares • NASDAQ
$1.19 ▲ 2.59% (+0.03)
Market Cap $22.36 M
52w High $9.40
52w Low $0.91
Dividend Yield 0%
P/E -2.38
Volume 22.65K
Outstanding Shares 18.79M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2024 $7.446M ▲ $14.933M ▼ $7.671M ▼ $7.262M ▼
Q4-2023 $1.951M ▲ $16.309M ▼ $8.747M ▼ $7.562M ▲
Q2-2023 $943.58K ▼ $16.678M ▲ $9.862M ▼ $6.815M ▲
Q4-2022 $1.217M $15.381M $9.892M $5.489M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow

Five-Year Company Overview

Income Statement

Income Statement BMGL’s historical income statement looks very small and fairly flat, which is typical for a business that was still early and private during those years. Revenue appears minimal and roughly steady, with little to no operating profit. Net results hover around break-even, suggesting the company has been more focused on building a platform and positioning itself than on driving large-scale earnings so far. The listed earnings per share look positive but are more a reflection of a small base than of a mature, profit-rich business. The real test will be whether the recent contracts, acquisitions, and expansion plans translate into meaningful revenue and profit growth over the next few years.

Balance Sheet

Balance Sheet The balance sheet is very light, again reflecting a small, early-stage company prior to listing. Asset levels are low, with only modest equity and almost no reported cash in the historical snapshots. Debt appears limited and has actually been reduced, which is a positive sign for financial risk, but it also means the company has not yet built a large capital base. BMGL will likely need to strengthen its balance sheet over time—through retained earnings, new capital, or both—to support the ambitious growth, acquisitions, and technology rollouts it is targeting.

Cash Flow

Cash Flow Cash flow from operations and free cash flow have essentially been negligible in recent years. That tells you the business has not yet generated meaningful cash internally and has probably been relying on external funding or owner support to grow. Capital spending has also been minimal in the historical data, which does not yet reflect the more aggressive expansion and technology integration the company is now pursuing. The key risk is execution: BMGL must convert its contracts, acquisitions, and integrated ecosystem strategy into steady, recurring cash flows to sustain future growth without overreliance on outside financing.

Competitive Edge

Competitive Edge Competitively, BMGL is trying to carve out a niche as an integrated specialist healthcare group in Southeast Asia, anchored in orthopedics, sports medicine, trauma care, and neurosurgery. Its strategy centers on three pillars: an integrated network of clinics and imaging centers, AI-enhanced supply chain operations, and a broad suite of services that keep patients within its ecosystem from diagnosis through rehabilitation. The acquisition of Bethesda Medical and the large supply contract across Asia-Pacific are meaningful strategic steps that could broaden its reach and deepen its relationships. However, the company remains small in a region with strong hospital groups, insurers, and clinic chains, so its moat is still forming rather than fully established. Competitive pressure, regulatory rules, and the ability to attract top medical talent will be key ongoing challenges.

Innovation and R&D

Innovation and R&D BMGL’s innovation story rests more on applied technology and integration than on classic lab-style research. Its standout move is the deployment of AI in its supply chain to improve forecasting, inventory management, and distribution across Asia-Pacific, as well as early use of AI tools to help doctors interpret imaging more efficiently. The company is also innovating in how services are bundled—bringing diagnostics, specialist clinics, and surgical care under one roof to create a smoother patient journey. There is limited public detail on proprietary clinical technologies, so much of the innovation appears to be about systems, partnerships, and digital tools rather than unique drugs or devices. Future upside depends on how deeply BMGL embeds technology into everyday clinical workflows and how well it scales this model within and beyond Singapore.

Summary

BMGL is a very young, still-small healthcare group that has chosen an ambitious path: building an AI-enabled, integrated care ecosystem in a rapidly growing region. Historical financials show a tiny, near break-even operation that has not yet demonstrated strong revenue or cash generation, so the investment story is more about potential than past performance. On the positive side, the company has laid out a clear strategic direction—specialized care, integrated services, AI-enhanced logistics, and regional expansion supported by acquisitions and partnerships. The main risks center on scale, execution, and funding: BMGL must prove it can turn its contracts, acquisitions, and technology investments into durable revenue, solid margins, and reliable cash flows, all while competing against much larger incumbents. In short, this looks like an early-stage, high-ambition healthcare platform where the financial track record is thin, and the outcome will hinge on how well management delivers on its expansion and integration plans over the next several years.